@article{c9a3c37869624c009fceec74f7095f3a,
title = "Neuroprotection offered by mesenchymal stem cells in perinatal brain injury: Role of mitochondria, inflammation and reactive oxygen species",
abstract = "Preclinical studies have shown that mesenchymal stem cells have a positive effect in perinatal brain injury models. The mechanisms that cause these neurotherapeutic effects are not entirely intelligible. Mitochondrial damage, inflammation, and reactive oxygen species are considered to be critically involved in the development of injury. Mesenchymal stem cells have immunomodulatory action and exert mitoprotective effects which attenuate production of reactive oxygen species and promote restoration of tissue function and metabolism after perinatal insults. This review summarizes the present state, the underlying causes, challenges and possibilities for effective clinical translation of mesenchymal stem cell therapy. (Figure presented.).",
keywords = "inflammation, intraventricular hemorrhage, mesenchymal stem cells, mitochondria, mitophagy, neonatal brain injury, neonatal hypoxia-ischemia, reactive oxygen species",
author = "Syam Nair and Eridan Rocha-Ferreira and Bobbi Fleiss and Nijboer, {Cora H} and Pierre Gressens and Carina Mallard and Henrik Hagberg",
note = "Funding Information: The authors thank the support from the Swedish Medical Research Council (VR (2019‐01320; 2017‐01409, CM); the Swedish Governmental Grant to Researchers at University Hospitals (ALFGBG‐432291; ALFGBG‐722491, CM); Hj{\"a}rnfonden (Brain Foundation FO2019‐0056; FO2019‐0270, CM); ERA‐NET (Contract: 0755101), and EU (contract: 874721 Horizon 2020), Ahlen Foundation (HH, CM, SN), Tore Nilsons Foundation (2018‐00594, SN), Jane and Dan Olssson Foundation (2020‐25, SN), Stiftelsen Fru Mary Von Sydows (3616, SN), Hasselblad Foundation (2020‐2021, ERF), {\AA}ke Wibergs Foundation (M19‐0660, ERF), Fondation pour le Recherche M{\'e}dicale, Fondation Grace de Monaco, and an additional grant from Investissement d'Avenir (ANR‐11‐INBS‐0011) NeurATRIS, and the Cerebral Palsy Alliance (PG12518). Figure 1 has been re‐drawn by Marco Bazelmans in BioRender ( https://biorender.com/ ) on the basis of a draft provided by the author. Funding Information: The authors thank the support from the Swedish Medical Research Council (VR (2019-01320; 2017-01409, CM); the Swedish Governmental Grant to Researchers at University Hospitals (ALFGBG-432291; ALFGBG-722491, CM); Hj{\"a}rnfonden (Brain Foundation FO2019-0056; FO2019-0270, CM); ERA-NET (Contract: 0755101), and EU (contract: 874721 Horizon 2020), Ahlen Foundation (HH, CM, SN), Tore Nilsons Foundation (2018-00594, SN), Jane and Dan Olssson Foundation (2020-25, SN), Stiftelsen Fru Mary Von Sydows (3616, SN), Hasselblad Foundation (2020-2021, ERF), {\AA}ke Wibergs Foundation (M19-0660, ERF), Fondation pour le Recherche M{\'e}dicale, Fondation Grace de Monaco, and an additional grant from Investissement d'Avenir (ANR-11-INBS-0011) NeurATRIS, and the Cerebral Palsy Alliance (PG12518). Figure 1 has been re-drawn by Marco Bazelmans in BioRender (https://biorender.com/) on the basis of a draft provided by the author. Publisher Copyright: {\textcopyright} 2020 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.",
year = "2021",
month = jul,
doi = "10.1111/jnc.15267",
language = "English",
volume = "158",
pages = "59--73",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "1",
}